Compounds > pf 3512676
Page last updated: 2024-11-13

pf 3512676

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ProMune: an anticancer adjuvant and immunostimulant [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID56841790
MeSH IDM0516772

Synonyms (6)

Synonym
agatolimod
promune
pf 3512676
pf-3512676
cpg7909
gtpl9843

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" All vaccines were found to be generally well tolerated with similar frequency and intensity for most adverse reactions for groups receiving CPG 7909 as controls."( Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine.
Al Adhami, MJ; Cameron, DW; Cooper, CL; Davis, HL; Efler, SM; Khaliq, Y; Krieg, AM; Laframboise, C; Li, Y; Morris, ML; Seguin, I, 2004)		0.32
" All three dose levels of CpG 7909 were safe and not associated with significant clinical or laboratory abnormality."( Activation of innate immunity in healthy Macaca mulatta macaques by a single subcutaneous dose of GMP CpG 7909: safety data and interferon-inducible protein-10 kinetics for humans and macaques.
Angov, E; Brewer, TG; Heppner, DG; Krieg, AM; Larson, NS; McGrath, S; Smith, CL; Stewart, VA, 2008)		0.35
"54 mg/kg had dose-limiting toxicities (grade 3 nonhematologic adverse events [AEs], including anorexia)."( Safety and efficacy of PF-3512676 for the treatment of stage IV renal cell carcinoma: an open-label, multicenter phase I/II study.
Bukowski, RM; Drucker, BJ; Kuzel, T; Thompson, JA; Urba, WJ, 2009)		0.35
" Both vaccines were well tolerated, with only mild local adverse events and no systemic adverse events judged related to vaccination."( A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults.
Diallo, DA; Dicko, A; Dolo, A; Doumbo, OK; Ellis, RD; Fay, MP; Guindo, MA; Guindo, O; Kamate, B; Kante, O; Long, C; Martin, LB; Miller, LH; Miura, K; Mullen, GE; Niambele, MB; Pierce, M; Rausch, K; Sagara, I; Saye, R; Sissoko, MS, 2009)		0.35
"No serious adverse events were reported, although vaccines used in combination with PF03512676 had enhanced reactogenicity."( Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant.
Broyer, S; Couture, L; Dadwal, S; Denison, S; Diamond, DJ; Drake, J; Kaltcheva, T; Kelsey, MI; Krieg, AM; Kwon, P; La Rosa, C; Lacey, SF; Longmate, J; Marsano, D; Nakamura, R; Sharan, R; Williams, B; Zaia, JA, 2012)		0.38
" Our adjuvant regimen combining PF-3512676 and granulocyte macrophage-colony stimulating factor was safe and is worthy of further testing with these or alternative peptides, potentially in combination with antibodies that target immunoregulatory checkpoints."( Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in adjuvant with PF-3512676 and GM-CSF in metastatic melanoma.
Gooding, WE; Kirkwood, JM; Leng, S; Lin, Y; Moschos, SJ; Sander, C; Tarhini, AA; Yin, Y, 2012)		0.38
" The most common adverse events (AEs) in the BioThrax and AV7909 groups assessed as related to vaccination were injection site reactions."( Randomized, double-blind, placebo-controlled, safety and immunogenicity study of 4 formulations of Anthrax Vaccine Adsorbed plus CPG 7909 (AV7909) in healthy adult volunteers.
Bernton, E; Daczkowski, NF; Hopkins, RJ; Kaptur, PE; LaForce, C; Muse, D; Rudge, TL; Sari, S; Sheldon, E, 2013)		0.39
" The incidences of adverse events (AEs) were 79% for AV7909 subjects and 65% for BioThrax subjects; 92% of AV7909 subjects and 87% of BioThrax subjects having AEs reported Grade 1-2 AEs."( Randomized, double-blind, active-controlled study evaluating the safety and immunogenicity of three vaccination schedules and two dose levels of AV7909 vaccine for anthrax post-exposure prophylaxis in healthy adults.
Hampel, FC; Hopkins, RJ; Kalsi, G; Lemiale, L; Montalvo-Lugo, VM; Muse, DD; Sharma, M; Sheldon, EA; Wu, Y, 2016)		0.43

Compound-Compound Interactions

ExcerptReferenceRelevance
" Here, we report the results of a pilot trial designed to study the immunogenicity of the analog peptide NY-ESO-1 157-165V in combination with CpG 7909/PF3512676 and Montanide ISA 720 in patients with stage III/IV NY-ESO-1-expressing melanoma."( Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients.
Andrade Filho, PA; Donnenberg, A; Fourcade, J; Janjic, B; Kirkwood, JM; Krieg, A; Kudela, P; Land, SR; Sander, C; Shen, H; Zarour, HM, 2008)		0.35
"This phase I, open-label study investigated the Toll-like receptor 9 agonist, PF-3512676, in combination with carboplatin and paclitaxel in Japanese patients with advanced, non-small-cell lung cancer (NSCLC)."( Phase I study of TLR9 agonist PF-3512676 in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer.
Fukuyama, C; Hashimoto, J; Kunitoh, H; Nakao, M; Nokihara, H; Ohe, Y; Ohki, E; Sekine, I; Tamura, T; Yamada, K; Yamamoto, N, 2010)		0.36
" A phase I trial for advanced esophageal squamous cell carcinoma was carried out for patients with HLA-A*2402 using epitope peptides derived from novel cancer-testis antigens, LY6K and TTK, in combination with CpG-7909 (NCT00669292)."( Vaccination with peptides derived from cancer-testis antigens in combination with CpG-7909 elicits strong specific CD8+ T cell response in patients with metastatic esophageal squamous cell carcinoma.
Iida, T; Iwahashi, M; Katsuda, M; Naka, T; Nakamori, M; Nakamura, M; Ojima, T; Yamaue, H, 2010)		0.36
" To test safety and immunogenicity of a vaccine composed of WT1-, Pr3-, and MUC1-derived Class I-restricted peptides and the pan HLA-DR T helper cell epitope (PADRE) or MUC1-helper epitopes in combination with CpG7909 and MontanideISA51, four patients with AML and five with MM were repetitively vaccinated."( Pitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with MontanideISA51 and CpG7909.
Antunes, E; Davis, HL; de Boer, K; Greenberg, PD; Heit, W; Hol, S; Kuball, J; Lotz, C; Theobald, M; van Dorp, S; Vicari, AP; Wagner, E; Wattad, M; Weeratna, RD, 2011)		0.37
" Here, we determined whether an adjuvanted cancer vaccine can be safely administered with concomitant standard intravesical Bacillus-Calmette-Guérin (BCG) therapy and how vaccine-specific immune responses may be modulated in patients with non-muscle-invasive bladder cancer (NMIBC)."( Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.
Burruni, R; Cerantola, Y; Cesson, V; Dartiguenave, F; Derré, L; Fritschi, U; Gharbi, D; Jichlinski, P; Legris, AS; Lucca, I; Martin, V; Nardelli-Haefliger, D; Romero, P; Speiser, DE; Valerio, M; Vaucher, L; Vlamopoulos, Y, 2017)		0.46
"Cancer vaccines, including strong adjuvants, can be safely combined with intravesical BCG therapy."( Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.
Burruni, R; Cerantola, Y; Cesson, V; Dartiguenave, F; Derré, L; Fritschi, U; Gharbi, D; Jichlinski, P; Legris, AS; Lucca, I; Martin, V; Nardelli-Haefliger, D; Romero, P; Speiser, DE; Valerio, M; Vaucher, L; Vlamopoulos, Y, 2017)		0.46

Dosage Studied

ExcerptRelevanceReference
" For mice immunized with CPG 7909 bound to the AMA1-C1/Alhydrogel formulation, there was a bell shaped CPG 7909 dose-response curve with the highest antibody response co-incident with the concentration of CPG 7909 that saturated binding to the Alhydrogel."( Enhanced antibody production in mice to the malaria antigen AMA1 by CPG 7909 requires physical association of CpG and antigen.
Aebig, JA; Dobrescu, G; Lambert, L; Long, CA; Miles, AP; Mullen, GE; Rausch, K; Saul, A, 2007)		0.34
"A Phase 1 study was conducted in 24 malaria naïve adults to assess the safety and immunogenicity of the recombinant protein vaccine apical membrane antigen 1-Combination 1 (AMA1-C1)/Alhydrogel with CPG 7909 in two different formulations (phosphate buffer and saline), and given at two different dosing schedules, 0 and 1 month or 0 and 2 months."( A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel with CPG 7909, using two different formulations and dosing intervals.
Durbin, AP; Ellis, RD; Fay, MP; Long, CA; Martin, LB; Miller, LH; Miura, K; Mullen, GE; Pierce, M; Saul, A; Shaffer, D, 2009)		0.35
" Further studies of doses and dosing regimens are planned to assess the immunogenicity and reactogenicity of AV7909."( Randomized, double-blind, placebo-controlled, safety and immunogenicity study of 4 formulations of Anthrax Vaccine Adsorbed plus CPG 7909 (AV7909) in healthy adult volunteers.
Bernton, E; Daczkowski, NF; Hopkins, RJ; Kaptur, PE; LaForce, C; Muse, D; Rudge, TL; Sari, S; Sheldon, E, 2013)		0.39
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1345567Human TLR9 (Toll-like receptor family)2006Drugs in R&D, , Volume: 7, Issue:5
CpG 7909: PF 3512676, PF-3512676.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (89)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's36 (40.45)29.6817
2010's49 (55.06)24.3611
2020's4 (4.49)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.19

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.19 (24.57)
Research Supply Index4.97 (2.92)
Research Growth Index4.53 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.19)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials50 (53.76%)5.53%
Reviews7 (7.53%)6.00%
Case Studies1 (1.08%)4.05%
Observational0 (0.00%)0.25%
Other35 (37.63%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
mannitol
[no description available]		5.6132mannitolallergen;
antiglaucoma drug;
compatible osmolytes;
Escherichia coli metabolite;
food anticaking agent;
food bulking agent;
food humectant;
food stabiliser;
food thickening agent;
hapten;
metabolite;
osmotic diuretic;
sweetening agent
quinazolines
Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.. quinazoline : A mancude organic heterobicyclic parent that is naphthalene in which the carbon atoms at positions 1 and 3 have been replaced by nitrogen atoms.. quinazolines : Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.		4.3911azaarene;
mancude organic heterobicyclic parent;
ortho-fused heteroarene;
quinazolines
thiazoles
[no description available]		2.08101,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
deoxycytidine
[no description available]		3.4611pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
aluminum sulfate
aluminium sulfate (anhydrous) : An aluminium sulfate that contains no water of crystallisation.		2.0310aluminium sulfate
paclitaxel
Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).		5.2743taxane diterpenoid;
tetracyclic diterpenoid		antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent
imiquimod
Imiquimod: A topically-applied aminoquinoline immune modulator that induces interferon production. It is used in the treatment of external genital and perianal warts, superficial CARCINOMA, BASAL CELL; and ACTINIC KERATOSIS.. imiquimod : An imidazoquinoline fused [4,5-c] carrying isobutyl and amino substituents at N-1 and C-4 respectively. A prescription medication, it acts as an immune response modifier and is used to treat genital warts, superficial basal cell carcinoma, and actinic keratosis.		3.5520imidazoquinolineantineoplastic agent;
interferon inducer
gemcitabine
gemcitabine : A 2'-deoxycytidine having geminal fluoro substituents in the 2'-position. An inhibitor of ribonucleotide reductase, gemcitabine is used in the treatment of various carcinomas, particularly non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer.		3.4611organofluorine compound;
pyrimidine 2'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
antiviral drug;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
environmental contaminant;
immunosuppressive agent;
photosensitizing agent;
prodrug;
radiosensitizing agent;
xenobiotic
yttrium radioisotopes
Yttrium Radioisotopes: Unstable isotopes of yttrium that decay or disintegrate emitting radiation. Y atoms with atomic weights 82-88 and 90-96 are radioactive yttrium isotopes.		3.4711
docetaxel anhydrous
Docetaxel: A semisynthetic analog of PACLITAXEL used in the treatment of locally advanced or metastatic BREAST NEOPLASMS and NON-SMALL CELL LUNG CANCER.. docetaxel anhydrous : A tetracyclic diterpenoid that is paclitaxel with the N-benzyloxycarbonyl group replaced by N-tert-butoxycarbonyl, and the acetoxy group at position 10 replaced by a hydroxy group.		3.4311secondary alpha-hydroxy ketone;
tetracyclic diterpenoid		antimalarial;
antineoplastic agent;
photosensitizing agent
resiquimod
S 28463: structure given in first source		3.1210imidazoquinoline
erlotinib hydrochloride
[no description available]		4.3911hydrochloride;
terminal acetylenic compound		antineoplastic agent;
protein kinase inhibitor
carboplatin
[no description available]		5.0533
dasatinib
N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)-1,3-thiazole-5-carboxamide: a dasatinib prodrug; structure in first source. dasatinib (anhydrous) : An aminopyrimidine that is 2-methylpyrimidine which is substituted at position 4 by the primary amino group of 2-amino-1,3-thiazole-5-carboxylic acid and at position 6 by a 4-(2-hydroxyethyl)piperazin-1-yl group, and in which the carboxylic acid group has been formally condensed with 2-chloro-6-methylaniline to afford the corresponding amide. A multi-targeted kinase inhibitor, it is used, particularly as the monohydrate, for the treatment of chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia. Note that the name 'dasatinib' is used to refer to the monohydrate (USAN) as well as to anhydrous dasatinib (INN).		2.08101,3-thiazoles;
aminopyrimidine;
monocarboxylic acid amide;
N-(2-hydroxyethyl)piperazine;
N-arylpiperazine;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antineoplastic agent;
tyrosine kinase inhibitor
lipid a
Lipid A: Lipid A is the biologically active component of lipopolysaccharides. It shows strong endotoxic activity and exhibits immunogenic properties.. lipid A : The glycolipid moiety of bacterial lipopolysaccharide (R can be either hydrogen or a fatty acyl group).		3.5311dodecanoate ester;
lipid A;
tetradecanoate ester		Escherichia coli metabolite
mart-1 antigen
MART-1 Antigen: A melanosome-specific protein that plays a role in the expression, stability, trafficking, and processing of GP100 MELANOMA ANTIGEN, which is critical to the formation of Stage II MELANOSOMES. The protein is used as an antigen marker for MELANOMA cells.		6.2942
oligonucleotides
[no description available]		4.8221
rn486
RN486: a selective Bruton's tyrosine kinase inhibitor		2.110
dacarbazine
(E)-dacarbazine : A dacarbazine in which the N=N double bond adopts a trans-configuration.		3.4311dacarbazine
ConditionIndicatedRelationship StrengthStudiesTrials
Diffuse Mixed Small and Large Cell Lymphoma
[description not available]		06.5232
Lymphoma, Non-Hodgkin
Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.		06.5232
Bacillus anthracis Infection
[description not available]		06.6854
Anthrax
An acute infection caused by the spore-forming bacteria BACILLUS ANTHRACIS. It commonly affects hoofed animals such as sheep and goats. Infection in humans often involves the skin (cutaneous anthrax), the lungs (inhalation anthrax), or the gastrointestinal tract. Anthrax is not contagious and can be treated with antibiotics.		06.6854
Minimal Disease, Residual
[description not available]		05.3922
Diffuse Lymphocytic Lymphoma, Poorly-Differentiated
[description not available]		04.5511
Lymphoma, Mantle-Cell
A form of non-Hodgkin lymphoma having a usually diffuse pattern with both small and medium lymphocytes and small cleaved cells. It accounts for about 5% of adult non-Hodgkin lymphomas in the United States and Europe. The majority of mantle-cell lymphomas are associated with a t(11;14) translocation resulting in overexpression of the CYCLIN D1 gene (GENES, BCL-1).		04.5511
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.2510
Pulmonary Consumption
[description not available]		02.5920
Tuberculosis, Pulmonary
MYCOBACTERIUM infections of the lung.		02.5920
2019 Novel Coronavirus Disease
[description not available]		02.3110
Infusion Site Adverse Event
[description not available]		02.3110
Koch's Disease
[description not available]		02.5220
Tuberculosis
Any of the infectious diseases of man and other animals caused by species of MYCOBACTERIUM TUBERCULOSIS.		02.5220
Buckley Syndrome
[description not available]		02.1510
Job Syndrome
Primary immunodeficiency syndrome characterized by recurrent infections and hyperimmunoglobulinemia E. Most cases are sporadic. Of the rare familial forms, the dominantly inherited subtype has additional connective tissue, dental and skeletal involvement that the recessive type does not share.		02.1510
Delayed Effects, Prenatal Exposure
[description not available]		02.1710
Pregnancy
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.		02.1710
Lymph Node Metastasis
[description not available]		04.4511
Malignant Melanoma
[description not available]		09.511510
Local Neoplasm Recurrence
[description not available]		05.3722
Melanoma
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)		09.511510
Recrudescence
[description not available]		05.3222
HIV Coinfection
[description not available]		07.3155
HIV Infections
Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).		07.3155
Disease Exacerbation
[description not available]		04.732
Benign Neoplasms
[description not available]		07.6872
Cancer of Skin
[description not available]		07.2976
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		07.6872
Skin Neoplasms
Tumors or cancer of the SKIN.		07.2976
Carcinoma, Non-Small Cell Lung
[description not available]		08.0675
Cancer of Lung
[description not available]		08.0675
Carcinoma, Non-Small-Cell Lung
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.		08.0675
Lung Neoplasms
Tumors or cancer of the LUNG.		08.0675
Plasmodium falciparum Malaria
[description not available]		07.3155
Malaria, Falciparum
Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations.		07.3155
Asthma, Bronchial
[description not available]		02.1110
Asthma
A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).		02.1110
Blood Poisoning
[description not available]		04.4111
Adverse Drug Event
[description not available]		04.4111
Infections, Meningococcal
[description not available]		04.4111
Meningococcal Infections
Infections with bacteria of the species NEISSERIA MENINGITIDIS.		04.4111
Sepsis
Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.		04.4111
Drug-Related Side Effects and Adverse Reactions
Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.		04.4111
Cytomegalic Inclusion Disease
[description not available]		05.8322
Graft-Versus-Host Disease
[description not available]		04.4311
Viremia
The presence of viruses in the blood.		04.4311
Cytomegalovirus Infections
Infection with CYTOMEGALOVIRUS, characterized by enlarged cells bearing intranuclear inclusions. Infection may be in almost any organ, but the salivary glands are the most common site in children, as are the lungs in adults.		05.8322
Cytomegalovirus
A genus of the family HERPESVIRIDAE, subfamily BETAHERPESVIRINAE, infecting the salivary glands, liver, spleen, lungs, eyes, and other organs, in which they produce characteristically enlarged cells with intranuclear inclusions. Infection with Cytomegalovirus is also seen as an opportunistic infection in AIDS.		04.7721
Graft vs Host Disease
The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION.		04.4311
Bladder Cancer
[description not available]		03.8621
Urinary Bladder Neoplasms
Tumors or cancer of the URINARY BLADDER.		03.8621
Carcinoma, Transitional Cell
A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.		03.5311
Colorectal Cancer
[description not available]		02.1310
Colorectal Neoplasms
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.		02.1310
Atherogenesis
[description not available]		02.9610
Atherosclerosis
A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA.		02.9610
Infections, Plasmodium
[description not available]		05.8242
Malaria
A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia.		05.8242
Breast Cancer
[description not available]		02.9710
Cancer of Ovary
[description not available]		02.9710
Sarcoma, Epithelioid
[description not available]		02.9710
Breast Neoplasms
Tumors or cancer of the human BREAST.		02.9710
Ovarian Neoplasms
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.		02.9710
Sarcoma
A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.		02.9710
Adenocarcinoma Of Kidney
[description not available]		03.4311
Cancer of Kidney
[description not available]		03.4311
Carcinoma, Renal Cell
A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.		03.4311
Kidney Neoplasms
Tumors or cancers of the KIDNEY.		03.4311
AIDS-Related Opportunistic Infections
Opportunistic infections found in patients who test positive for human immunodeficiency virus (HIV). The most common include PNEUMOCYSTIS PNEUMONIA, Kaposi's sarcoma, cryptosporidiosis, herpes simplex, toxoplasmosis, cryptococcosis, and infections with Mycobacterium avium complex, Microsporidium, and Cytomegalovirus.		04.3611
B-Cell Lymphoma
[description not available]		014.584949
Lymphoma, B-Cell
A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.		014.584949
Carcinoma, Epidermoid
[description not available]		04.3611
Cancer of Esophagus
[description not available]		04.3611
Carcinoma, Squamous Cell
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)		04.3611
Esophageal Neoplasms
Tumors or cancer of the ESOPHAGUS.		04.3611
Cutaneous T-Cell Lymphoma
[description not available]		04.3611
Lymphoma, T-Cell, Cutaneous
A group of lymphomas exhibiting clonal expansion of malignant T-lymphocytes arrested at varying stages of differentiation as well as malignant infiltration of the skin. MYCOSIS FUNGOIDES; SEZARY SYNDROME; LYMPHOMATOID PAPULOSIS; and PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL LYMPHOMA are the best characterized of these disorders.		04.3611
Kahler Disease
[description not available]		03.4511
Acute Myelogenous Leukemia
[description not available]		03.8321
Multiple Myeloma
A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.		03.4511
Leukemia, Myeloid, Acute
Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.		03.8321
Cancer of Prostate
[description not available]		04.3711
Prostatic Neoplasms
Tumors or cancer of the PROSTATE.		04.3711
T-Cell Lymphoma
[description not available]		02.0710
Lymphoma, T-Cell
A group of heterogeneous lymphoid tumors representing malignant transformations of T-lymphocytes.		02.0710
B-Cell Chronic Lymphocytic Leukemia
[description not available]		03.8621
Leukemia, Lymphocytic, Chronic, B-Cell
A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease.		03.8621
Infectious Diseases
[description not available]		02.9910
Allergic Reaction
[description not available]		02.9910
Communicable Diseases
An illness caused by an infectious agent or its toxins that occurs through the direct or indirect transmission of the infectious agent or its products from an infected individual or via an animal, vector or the inanimate environment to a susceptible animal or human host.		02.9910
Hypersensitivity
Altered reactivity to an antigen, which can result in pathologic reactions upon subsequent exposure to that particular antigen.		02.9910
Metastase
[description not available]		05.9633
Neoplasm Metastasis
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.		05.9633
Bilateral Headache
[description not available]		04.3711
Headache
The symptom of PAIN in the cranial region. It may be an isolated benign occurrence or manifestation of a wide variety of HEADACHE DISORDERS.		04.3711
Diseases of Immune System
[description not available]		02.0810
Immune System Diseases
Disorders caused by abnormal or absent immunologic mechanisms, whether humoral, cell-mediated, or both.		02.0810
Hepatitis B Virus Infection
[description not available]		04.3722
Hepatitis B
INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.		04.3722
Genetic Predisposition
[description not available]		02.9410
Alcohol Abuse
[description not available]		02.9410
Alcohol Drinking
Behaviors associated with the ingesting of ALCOHOLIC BEVERAGES, including social drinking.		02.9410
Alcoholism
A primary, chronic disease with genetic, psychosocial, and environmental factors influencing its development and manifestations. The disease is often progressive and fatal. It is characterized by impaired control over drinking, preoccupation with the drug alcohol, use of alcohol despite adverse consequences, and distortions in thinking, most notably denial. Each of these symptoms may be continuous or periodic. (Morse & Flavin for the Joint Commission of the National Council on Alcoholism and Drug Dependence and the American Society of Addiction Medicine to Study the Definition and Criteria for the Diagnosis of Alcoholism: in JAMA 1992;268:1012-4)		02.9410
Experimental Neoplasms
[description not available]		02.0310
Francisella tularensis Infection
[description not available]		02.0310
Tularemia
A plague-like disease of rodents, transmissible to man. It is caused by FRANCISELLA TULARENSIS and is characterized by fever, chills, headache, backache, and weakness.		02.0310
Innate Inflammatory Response
[description not available]		02.9610
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.9610
Cancer of Liver
[description not available]		02.0410
Cancer of Pelvis
[description not available]		02.0410
Cancer of Spleen
[description not available]		02.0410
Liver Neoplasms
Tumors or cancer of the LIVER.		02.0410
Necrosis
The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.		02.0410
Carcinoma, Basal Cell, Pigmented
[description not available]		03.4311
Carcinoma, Basal Cell
A malignant skin neoplasm that seldom metastasizes but has potentialities for local invasion and destruction. Clinically it is divided into types: nodular, cicatricial, morphaic, and erythematoid (pagetoid). They develop on hair-bearing skin, most commonly on sun-exposed areas. Approximately 85% are found on the head and neck area and the remaining 15% on the trunk and limbs. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1471)		03.4311